Int J Cardiol:急性冠脉综合征后患者发生心力衰竭的预测因素!

2017-07-03 xing.T MedSci原创

由此可见,添加一个多生物标志物到常规参数模型中可明显改善对未来心衰事件的识别和风险分类。

冠心病是心力衰竭的主要原因,可用的包括临床参数和生物标志物的风险预测模型十分有限。近日,心血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,研究人员的目的是建立一个这样的预测心力衰竭的模型。

研究人员建立了一个预测心力衰竭死亡或住院的多变量危险因素模型。得出一个简化的风险评分将受试者归类为5年风险从<5%到>20%不等的类别。

在LIPID研究中的7101例患者(84%名男性),平均年龄为61岁(四分位距为55-67岁),558例(8%)患者发生死亡或因心衰住院。年龄较大、跛行或糖尿病史、体重指数大于30kg/m2、低密度脂蛋白胆固醇>2.5mmol/L、心率>70次/分、血白细胞计数和急性冠状动脉综合征的性质(心肌梗死或不稳定型心绞痛)与心力衰竭事件的增加相关。冠状动脉血运重建与较低的事件发生率相关。心衰发生率随着较高浓度的B型钠尿肽>50ng/L、血清胱抑素C>0.93nmol/L、D-dimer>273nmol/L、高敏C反应蛋白>4.8nmol/L、敏感的肌钙蛋白I>0.018μg/L而有所增加。将生物标志物增加到临床风险模型中可以改善模型的C统计从0.73到0.77。将生物标志物加入到临床模型的净重分类改进中5年风险为23%。

由此可见,添加一个多生物标志物到常规参数模型中可明显改善对未来心衰事件的识别和风险分类。

原始出处:


Andrea Driscoll,et al. Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2017.06.098

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781779, encodeId=a7c21e8177989, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 30 02:30:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264249, encodeId=b01d12642491a, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430880, encodeId=e5051430880c8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218207, encodeId=651a21820ea2, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 03 18:49:48 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781779, encodeId=a7c21e8177989, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 30 02:30:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264249, encodeId=b01d12642491a, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430880, encodeId=e5051430880c8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218207, encodeId=651a21820ea2, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 03 18:49:48 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781779, encodeId=a7c21e8177989, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 30 02:30:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264249, encodeId=b01d12642491a, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430880, encodeId=e5051430880c8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218207, encodeId=651a21820ea2, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 03 18:49:48 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781779, encodeId=a7c21e8177989, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Sep 30 02:30:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264249, encodeId=b01d12642491a, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430880, encodeId=e5051430880c8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 05 07:30:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218207, encodeId=651a21820ea2, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 03 18:49:48 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-03 131****1460

    学习了受益匪浅。

    0

相关资讯

Heart:≤55岁急性冠脉综合征患者前驱症状有何性别差异?

2017年6月,发表在《Heart》的一项由加拿大科学家进行的研究考察了55岁或以下的急性冠脉综合征(ACS)患者前驱症状的性别差异。

JACC:经桡动脉或股动脉侵入性治疗急性冠脉综合征后的肾损伤

在接受侵入性治疗的ACS患者中,与FA相比RA与AKI的风险降低相关。

Int J Clin Pharm:急性冠脉综合征住院患者发生用药差错有多频繁?

2017年6月,发表在《Int J Clin Pharm》的一项由埃及科学家进行的研究,考察了急性冠脉综合征住院患者发生用药差错的的频率、主要类型和预测因素。

Circulation:吡格列酮能否降低缺血性卒中或短暂缺血发作后的ACS风险?

胰岛素抵抗在动脉粥样硬化患者中发病率较高,并与心梗(MI)和卒中风险的增加相关。IRIS试验证实,吡格列酮会降低不合并糖尿病的胰岛素抵抗患者近期缺血性卒中或短暂缺血发作后的致命性或非致命性卒中和MI的复合风险。该人群中,心脏事件的类型和严重程度以及吡格列酮对这些事件的影响尚未进行过描述。2017年5月,《Circulation.》的一项研究对此进行分析。

Lancet:急性冠脉综合征临床显著出血:P2Y12抑制剂+利伐沙班vs阿司匹林

2017年5月,发表在《Lancet》的一项研究调查了急性冠脉综合征患者使用P2Y12抑制剂+低剂量利伐沙班vs阿司匹林的临床显着出血风险。背景:阿司匹林联合P2Y12抑制剂的双重抗血小板疗法(DAPT)是急性冠脉综合征后标准的抗血栓形成疗法。Xa因子抑制剂利伐沙班与DAPT联合使用时,可以降低死亡率和缺血性事件,但增加了出血风险。尚无低剂量利伐沙班(代替阿司匹林)和P2Y12抑制剂联合的双重通路

Eur Heart J: 急性冠脉综合征后双重抗血小板治疗中,普拉格雷+替卡格雷vs氯吡格雷

近年来急性冠脉综合征(ACS)的发病率呈上升趋势。ACS发生的关键是血小板活化聚集,我国目前治疗ACS使用最广泛的是低剂量阿司匹林联合P2Y12受体拮抗剂的方案。氯吡格雷是目前我国应用最广的P2Y12受体拮抗剂,但它是一种前体药物,存在起效 慢、药物抵抗、对P2Y12受体不逆性抑制、停药后血小板功能恢复时间长等缺点。既往的研究证明在缺血性ACS后使用新型P2Y12受体阻滞剂(普拉格雷和替卡格